Connect:        


All Releases
View Summary Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR
Feb 24, 2017
PDF 19.5 KB Add to Briefcase
View Summary Intellipharmaceutics Announces 2016 Year End Results
Feb 10, 2017
PDF 48.0 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Feb 2, 2017
PDF 21.5 KB Add to Briefcase
View Summary Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
Jan 6, 2017
PDF 18.9 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the Biotech Showcase™
Dec 29, 2016
PDF 17.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose Technology
Dec 21, 2016
PDF 20.8 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the LD Micro Main Event
Nov 29, 2016
PDF 17.7 KB Add to Briefcase
View Summary Intellipharmaceutics Submits New Drug Application for Rexista® (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Nov 25, 2016
PDF 21.9 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference
Oct 14, 2016
PDF 18.4 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Third Quarter 2016 Results
Oct 13, 2016
PDF 45.8 KB Add to Briefcase
View Summary Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt
Oct 11, 2016
PDF 23.4 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR®
Oct 7, 2016
PDF 19.6 KB Add to Briefcase
View Summary Intellipharmaceutics Responds to Recent Trading Activity
Sep 22, 2016
PDF 17.6 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
Aug 25, 2016
PDF 18.9 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Second Quarter 2016 Results
Jul 13, 2016
PDF 42.5 KB Add to Briefcase
View Summary Intellipharmaceutics Reports Update on Rexista™ XR: FDA Grants Waiver of NDA Filing Fee, and Topline Pharmacokinetics Results Indicate No Food Effect
Jul 5, 2016
PDF 21.8 KB Add to Briefcase
View Summary Intellipharmaceutics Closes Public Offering for US$5.2 Million
Jun 6, 2016
PDF 18.8 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
May 27, 2016
PDF 18.0 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
May 26, 2016
PDF 17.2 KB Add to Briefcase
View Summary Intellipharmaceutics Reports Director Election Results
Apr 19, 2016
PDF 18.7 KB Add to Briefcase
Showing 1-20 of 139 Page: 1 2 3 ... 7  Next 20
=add release to Briefcase